Literature DB >> 1381298

Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals.

C Gryllis1, M A Wainberg, Z Bentwich, M Gornitsky, B G Brenner.   

Abstract

The role of natural killer (NK) cells and their inducible counterparts, lymphokine-activated killer (LAK) cells in AIDS with regard to HIV-1 viral immunosurveillance and the control of secondary opportunistic disease has yet to be established. In this study, we have demonstrated that LAK cells derived from all HIV-1+ groups showed striking increases in their capacity to lyse HIV-1-infected U-937 cells relative to their uninfected U-937 counterparts. Surprisingly, similarly derived LAK cells from healthy seronegative controls showed no differences in their lysis of HIV-1-infected versus uninfected U-937 cells. The differential ability of LAK effectors from seropositive donors to lyse HIV-1-infected targets was demonstrable using a number of U-937 subclones and their HIV-1-infected counterparts. Again, no differences in LAK cell-mediated lysis of HIV-1-infected and uninfected U-937 subclones were observed in seronegative individuals. Our findings that HIV-1+ individuals show selective expansion of non-MHC restricted, HIV-1-directed cytotoxic LAK cells indicate that natural immunity may indeed play a role in HIV-1 viral immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381298      PMCID: PMC1554484          DOI: 10.1111/j.1365-2249.1992.tb06962.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin.

Authors:  M C Sirianni; S Soddu; W Malorni; G Arancia; F Aiuti; S Soddus
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

2.  Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.

Authors:  C Gambacorti-Passerini; L Rivoltini; M Radrizzani; F Belli; G Sciorelli; F Ravagnani; A R Galazka; N Cascinelli; G Parmiani
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

Review 3.  NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection.

Authors:  A S Fauci; S M Schnittman; G Poli; S Koenig; G Pantaleo
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

4.  In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates.

Authors:  J Chehimi; S Bandyopadhyay; K Prakash; B Perussia; N F Hassan; H Kawashima; D Campbell; J Kornbluth; S E Starr
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

Review 5.  Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness.

Authors:  J R Ortaldo; D L Longo
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

6.  Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome.

Authors:  T W Chin; S Plaeger-Marshall; A Haas; B J Ank; E R Stiehm
Journal:  Clin Immunol Immunopathol       Date:  1989-12

Review 7.  Characterization of functional surface structures on human natural killer cells.

Authors:  J Ritz; R E Schmidt; J Michon; T Hercend; S F Schlossman
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

8.  Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.

Authors:  J D Katz; R Mitsuyasu; M S Gottlieb; L T Lebow; B Bonavida
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

9.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

Authors:  J H Phillips; B T Gemlo; W W Myers; A A Rayner; L L Lanier
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

10.  Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection.

Authors:  F Vuillier; N E Bianco; L Montagnier; G Dighiero
Journal:  AIDS Res Hum Retroviruses       Date:  1988-04       Impact factor: 2.205

View more
  4 in total

1.  Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA.

Authors:  Baris E Dayanc; Sanjay Bansal; Ali Osmay Gure; Sandra O Gollnick; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2013-08       Impact factor: 3.914

2.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

3.  Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.

Authors:  B G Brenner; M Gornitsky; M A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

Review 4.  Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection.

Authors:  B G Brenner; M A Wainberg
Journal:  Infect Dis Obstet Gynecol       Date:  1999
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.